Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

CRISPR Therapeutics AG (NASDAQ:CRSP – Get Free Report) has earned a consensus recommendation of “Hold” from the nineteen ...

Bank of America Securities analyst Alec Stranahan maintained a Hold rating on Perspective Therapeutics (CATX – Research Report) yesterday and ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Colossal Biosciences wants to bring back the woolly mammoth and has raised $200 million at a $10.2 billion valuation to do it ...

Department of Health and Human Services (HHS) secretary nominee Robert F. Kennedy Jr. plans to continue to receive referral fees from a law firm that is suing pharma powerhouse Merck & Co. | ...

Lamm said this phase has been completed for the mammoth and the thylacine, and now the company’s scientists are using the gene-editing tool CRISPR to ... through the sale of biodiversity credits ...

Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma have ... transaction by selling 600,000 shares of the company. The sale was documented in a recent SEC Filing.

Securities.io is not an investment adviser, and this does not constitute investment advice, financial advice, or trading advice. Securities.io does not recommend that any security should be bought, ...

In a report released yesterday, Terence Flynn from Morgan Stanley maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), ...